IRIS
LUS, Giacomo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.169
NA - Nord America 3.984
AS - Asia 3.163
SA - Sud America 607
AF - Africa 46
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 4
Totale 12.978
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.912
RU - Federazione Russa 1.941
SG - Singapore 1.253
IE - Irlanda 951
CN - Cina 767
IT - Italia 555
BR - Brasile 536
HK - Hong Kong 536
UA - Ucraina 429
GB - Regno Unito 393
DE - Germania 331
KR - Corea 154
FR - Francia 152
VN - Vietnam 141
FI - Finlandia 126
SE - Svezia 87
IN - India 80
TR - Turchia 71
GR - Grecia 68
JP - Giappone 45
AR - Argentina 38
MX - Messico 31
BE - Belgio 29
CA - Canada 26
HU - Ungheria 21
IR - Iran 20
BD - Bangladesh 16
AT - Austria 15
ID - Indonesia 14
IQ - Iraq 13
NL - Olanda 13
PL - Polonia 13
ZA - Sudafrica 12
PK - Pakistan 11
CZ - Repubblica Ceca 9
EC - Ecuador 9
ES - Italia 9
MA - Marocco 8
TN - Tunisia 8
CO - Colombia 7
AE - Emirati Arabi Uniti 6
CH - Svizzera 6
EG - Egitto 5
IL - Israele 5
UZ - Uzbekistan 5
JO - Giordania 4
KE - Kenya 4
KZ - Kazakistan 4
LT - Lituania 4
PY - Paraguay 4
RS - Serbia 4
VE - Venezuela 4
AU - Australia 3
BG - Bulgaria 3
BO - Bolivia 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
EU - Europa 3
HN - Honduras 3
LB - Libano 3
SA - Arabia Saudita 3
UY - Uruguay 3
BB - Barbados 2
BY - Bielorussia 2
CR - Costa Rica 2
KG - Kirghizistan 2
NZ - Nuova Zelanda 2
OM - Oman 2
PA - Panama 2
PE - Perù 2
PH - Filippine 2
PT - Portogallo 2
TT - Trinidad e Tobago 2
AO - Angola 1
AZ - Azerbaigian 1
CG - Congo 1
CL - Cile 1
DK - Danimarca 1
DZ - Algeria 1
GA - Gabon 1
IS - Islanda 1
KW - Kuwait 1
MD - Moldavia 1
MK - Macedonia 1
MY - Malesia 1
NG - Nigeria 1
NO - Norvegia 1
NP - Nepal 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 12.978
Salva come PNG Salva come JPEG
Città #
Dublin 951
Moscow 640
Santa Clara 626
Jacksonville 594
Chandler 578
Hong Kong 532
Singapore 465
Seoul 152
Ann Arbor 146
Princeton 143
Beijing 141
Hefei 133
Roxbury 112
Medford 99
Bremen 96
Ashburn 94
Caserta 88
Dallas 88
Naples 83
The Dalles 70
Boardman 68
Munich 64
New York 60
Wilmington 59
Woodbridge 57
Bengaluru 50
Cambridge 50
Ho Chi Minh City 50
São Paulo 45
San Mateo 39
Los Angeles 37
Brussels 27
Milan 27
Hanoi 25
Norwalk 24
Des Moines 22
Nuremberg 20
Aversa 19
Jinan 18
Rio de Janeiro 18
Helsinki 17
Houston 16
Dong Ket 14
Nanjing 14
Rome 14
Tianjin 14
Turku 14
Belo Horizonte 11
Redwood City 11
Curitiba 10
Falkenstein 10
Guarulhos 10
Luzzano 10
Mountain View 10
Düsseldorf 9
Porto Alegre 9
San Francisco 9
Seattle 9
Auburn Hills 8
Brasília 8
Joinville 8
Siano 8
Vienna 8
Boston 7
Chicago 7
Columbus 7
Cuiabá 7
Guangzhou 7
Mexico City 7
Napoli 7
Stockholm 7
Taizhou 7
Toronto 7
Warsaw 7
Zhengzhou 7
Amsterdam 6
Baghdad 6
Bauru 6
Biên Hòa 6
Casablanca 6
Changsha 6
Hangzhou 6
Hyderabad 6
Karachi 6
Phoenix 6
Shenyang 6
Thái Bình 6
West Jordan 6
Chennai 5
Harbin 5
Lanzhou 5
Nanchang 5
Quarto 5
Reggio Nell'emilia 5
Ribeirão Preto 5
Salerno 5
Santa Maria 5
Tashkent 5
Amman 4
Ankara 4
Totale 7.081
Salva come PNG Salva come JPEG
Nome #
INSOLITO PNEUMOCEFALO IPERTESO DA OSTEOMA DEL SENO FRONTALE 194
Abnormal accumulation of tTGase products in muscle and erythrocytes of chorea-acanthocytosis patients 151
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. 145
Modifications moleculaires au cours de la regeneration et reinnervation musculaires in vitro 134
A cluster of progranulin C157KfsX97 mutations in Southern Italy: clinical characterization and genetic correlations 131
Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment. 122
Synergistic Interplay between Curcumin and Polyphenol-Rich Foods in the Mediterranean Diet: Therapeutic Prospects for Neurofibromatosis 1 Patients 122
Chronic HCV infection and neurological and psychiatric disorders: an overview. 115
Adiponectin profile at baseline is correlated to progression and severity of multiple sclerosis 115
Malattie dei nervi periferici 109
12-months prospective Pentraxin-3 and metabolomic evaluation in multiple sclerosis patients treated with glatiramer acetate 109
Biochemical and morphological evidences supporting the hypothesis of a role of Tgase in the pathogeneisi of Chorea-Acanthocytosis 108
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 107
Biochemical and morphological evidences supporting the hypothesis of a role of TGase in the pathogenesis of chorea acanthocytosis (C-A) 104
[Ambulatory monitoring of arterial pressure in the diagnosis and therapeutic evaluation of dysautonomic diseases: observations in a case of Shy-Drager syndrome] 100
Myoplasticity and myoregeneration; from molecular aspects to clinical perspectives 100
Biochemical and morphological evidences supporting the hypothesis of a role of TGase in the pathogenesis of chorea acanthocytosis (C-A) 100
Rasagiline improves sleep disorders in Parkinson's disease 100
Alemtuzumab significantly improves posterior fossa syndrome presented as a relapse of multiple sclerosis 100
[Unusual histo-cytopathologic findings in a familial case of stiff spine syndrome] 99
A new tRNAHis mutation in the mtDNA results in mitochondrial encephalomyopathy by hampering ATP production 99
Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis 99
Analisi in istofluorescenza di densità e distribuzione dei recettori per ConA e WGA in corso di rigenerazione e re-innervazione nel muscolo scheletrico di ratto ischemizzato e denervato, reversibilmente o irreversibilmente 98
Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis 98
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis 98
Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. 97
NEURO-DEGENERAZIONE CON ACCUMULO CEREBRALE DI FERRO TIPO 1 (NIBA TIPO1), UNA NUOVA FAMIGLIA CON MALATTIA DI HALLERVORDEN SPATZ A DECORSO CLINICO PROTRATTO 97
Autoantibodies in multiple sclerosis patients before and during IFN-β1b treatment: Are they correlated with the occurrence of autoimmune diseases? 96
Preliminary results of the FASM study, an on-going italian active pharmacovigilance project 95
An unusual phenotype of familial motor and sensory neuropathy with morphological features of HMSN1 94
CECITÀ E DIPLOPIA COME ESPRESSIONE ISOLATA DI METASTASI MESENCEFALICHE: CONSIDERAZIONI NEURORADIOLOGICHE, NEUROLOGICHE E NEUROCHIRURGICHE A PROPOSITO DI DUE CASI” 94
Retrospective epidemiology of Duchenne muscular dystrophy in Molise 92
Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment. 92
Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. 92
A cluster of progranulin C157KfsX97 mutation in southern Italy- clinical characterization and genetic correlations 92
Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease 92
Myopathic changes in neurofibromatosis type 1 91
Cecità e diplopia come espressione isolata di metastasi mesencefalica:considerazioni neuroradiologiche neurologiche e neurochirurgiche.A proposito di 2 casi 91
Are giant axons a pathological marker of charcot-marie-tooth neuropathy type 2E? 90
39. Density and distribution of ConA and WGA receptors determined by histofluorescence analysis during degeneration, regeneration and reinnervation of the rat skeletal muscle following ischemia and reversible or irreversible denervation. , : , 90
Angiogenesis and Multiple Sclerosis Pathogenesis: A Glance at New Pharmaceutical Approaches 89
CTG repeat number in the nonaffected allele of myotonic dystrophy patients is not critical for disease expression 89
Unusual manifestation of vertebral osteoid osteoma: case report 89
Animal model to study factors influencing regeneration and direct innervation or neurotization of skeletal muscle 89
Fingolimod efficacy in multiple sclerosis associated with Sjogren syndrome 88
Reperti isto e citopatologici del tutto peculiari riscontrati in un caso familiare di sindrome della spina rigida 88
C’È UN GUADAGNO DIAGNOSTICO IN RM DELLE SACNSIONI TARDIVE OPO DOSE TRIPLA DI GADOLINIO NELL’IDENTIFICAZIONE DI PLACCHE ATTIVE DI SCLEROSI MULTIPLA? * Risultati preliminari 88
Histopathological heterogeneity and cytopathological similarity of findings in different muscles of two brothers affected by rigid spine syndrome 87
La capacità rigenerativa del muscolo scheletrico danneggiato: studio sperimentale 87
LA NEUROMIELITE OTTICA È UN’ ASSOCIAZIONE SINDROMICA COMUNE A PATOLOGIE ETEROGENEE 87
BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab 87
Isolated transient blindness and isolated oculomotor nerve palsy secondary to single mesencephalic metastases: report of 2 cases 86
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 86
Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence 85
Apparently isolated CNS involvement in Erdheim-Chester disease: Case report 85
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration 85
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study 84
Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study. 84
Revelation of a new mitochondrial DNA mutation (G12147A) in a MELAS/MERFF phenotype. 84
Assessment of Multiple Sclerosis Disability Progression Using a Wearable Biosensor: A Pilot Study 84
Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice. 83
Progressive rubella panencephalitis. Follow-up EEG study of a case 83
Prognostic indicators in pediatric clinically isolated syndrome 83
Clinical and Genetic Heterogeneity in a Large Family with Pseudoxanthoma Elasticum: MTHFR and SERPINE1 Variants as Possible Disease Modifiers in Developing Ischemic Stroke 83
Disability assessment using Google Maps 83
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab 83
Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity 82
Cd19 cell count at baseline predicts b cell repopulation at 6 and 12 months in multiple sclerosis patients treated with ocrelizumab 82
Fluctuations of MS births and UV-light exposure. 81
Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases 81
CORRELATI CLINICO-STRUMENTALI IN UN CASO DI CREUTZFELD- JACOB A LUNGA SOPRAVVIVENZA. 81
Migraine as possible red flag of PFO presence in suspected demyelinating disease 81
Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study 81
Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case–control study 81
Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study 80
Atorvastatin Combined To Interferon to Verify the Efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy 79
Dalla malattia di Schilder all’adrenoleucodistrofia; una breve storia di un secolo di ricerca neuropatologica clinica esemplare 79
The Rise of the GRN C157KfsX97 Mutation in Southern Italy: Going Back to the Fall of the Western Roman Empire 79
Correction to: Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease 79
The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders 78
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests 78
Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment. 77
A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting 77
A real-world study of alemtuzumab in a cohort of Italian patients 77
Long-term effects of asymmetrical posture in boxing assessed by baropodometry 77
Health related quality of life in the domain of physical activity predicts confirmed disability progression in people with relapsing remitting multiple sclerosis 75
Neutralizing antibodies in multiple sclerosis patients treated with 375 microg interferon-beta-1b 75
Dalla malattia di Schilder alla adrenoleucodistrofia: una breve storia di un secolo di ricerca neuropatologica clinica esemplare 75
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 73
The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis 73
NEURO-DEGENERAZIONE ASSOCIATA A PANTOTENATO- CHINASI (MALATTIA DI HALLERVORDEN – SPATZ) IN UNA FAMIGLIA ITALIANA: CORRELAZIONI CLINICHE,MRI E GENETICHE 73
AZATIOPRINA E INTERFERONE - 1° NEI PAZIENTI CON SCLEROSI MULTIPLA RECIDIVANTE REMITTENTE: INCREMENTO DELL’EFFICACIA DEL TRATTAMENTO COMBINATO. 73
Therapeutic Plasmapheresis: a revision of literature 72
Signs and symptoms of COVID-19 in patients with multiple sclerosis 72
Normalization of short-chain acylcoenzyme A dehydrogenase after riboflavin treatment in a girl with multiple acylcoenzyme A dehydrogenase-deficient myopathy 72
Charcot-Marie-Tooth disease with giant axons: a clinicopathological and genetic entity 72
Monitoraggio biologico e sorveglianza sanitaria ai lavoratori esposti a bromuro di metile 72
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 72
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis 71
The Italian multiple sclerosis register 71
Totale 9.082
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.679
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.679
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021524 0 0 0 0 0 17 130 102 22 122 88 43
2021/20221.067 52 132 10 27 292 9 27 34 37 68 97 282
2022/20232.026 171 36 32 185 240 179 2 134 923 20 60 44
2023/2024731 70 21 48 56 252 60 10 25 6 3 57 123
2024/20252.675 6 45 40 74 399 406 298 201 393 420 235 158
2025/20264.229 323 424 556 524 895 1.507 0 0 0 0 0 0
Totale 13.377